engleski

Prevention of relapse with risperidone long-acting injectable antipsychotic in first-episode schizophrenic patients

Objective: Aim of the paper is to assess the therapeutic effieciency and relapse prevention of risperidone long-acting injectable (RLAI) antipsychotic in first-episode schizophrenia compared to those with two, three or more episodes. Treating patients with risperidone long-acting injectable antipsychotic avoids the issue of non-compliance which leads to lower relapse rates, better remission and recovery. Methods: The research included 48 patients aged 13 to 28 years who were diagnosed in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. They were divided into three groups according to the number of psychotic episodes. All patients were assessed four times over one year using the following clinical scales: Positive and Negative Syndrome Scale, Clinical Global Impression – Severity and Improvement Scale, Personal and Social Performance Scale. Result: First-episode patients had a better response to treatment with risperidone long-acting injectable antipsychotic when compared to second episode patients and much better compared to the third or more episode patients. Conclusion: Earlier application of risperidone long-acting injectable antipsychotic results in lower relape rates, better reaction to therapy, achieving remission and full recovery, especially in first-episode patients.

prevention of relapse ; risperidone ; schizophrenic patients

nije evidentirano